Search

Your search keyword '"CHRONIC hepatitis B"' showing total 2 results
2 results on '"CHRONIC hepatitis B"'

1. Disparities in Antiviral Treatment Among Adults With Hepatitis B Cirrhosis: An Analysis of the National Veterans Affairs Cohort.

Author

Wong, Robert J, Yang, Zeyuan, and Cheung, Ramsey

Subjects
*TREATMENT of cirrhosis of the liver, *COMPLICATIONS of alcoholism, *RESEARCH funding, *QUESTIONNAIRES, *MULTIPLE regression analysis, *CHRONIC hepatitis B, *DESCRIPTIVE statistics, *CHI-squared test, *MULTIVARIATE analysis, *HIGHLY active antiretroviral therapy, *LONGITUDINAL method, *RACE, *ODDS ratio, *VETERANS, *RURAL conditions, *STATISTICS, *HEALTH equity, *DATA analysis software, *CONFIDENCE intervals, *DISEASE progression, *ADULTS
Abstract

Timely antiviral therapy is critical in chronic hepatitis B cirrhosis to prevent further liver complications. Among a national cohort of US Veterans with chronic hepatitis B cirrhosis, only 52% were initiated on antiviral therapy; treatment was significantly lower among patients of non-Asian ethnicity, high-risk alcohol use, and in rural settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial.

Subjects
ACUTE myeloid leukemia, VENETOCLAX, CHRONIC hepatitis B, DRUG side effects, HEPATITIS C, TUMOR suppressor genes, ADULTS
Abstract

This document provides information about a clinical trial for the treatment of acute myeloid leukemia (AML) in older and unfit patients with FLT3 mutations. The trial aims to compare two treatment approaches: azacitidine and venetoclax versus azacitidine, venetoclax, and gilteritinib. Azacitidine activates cancer suppressor genes, venetoclax blocks a protein needed for cancer cell survival, and gilteritinib blocks the action of a substance that helps cancer cells multiply. The trial is not yet recruiting participants and is being conducted by the National Cancer Institute (NCI). The estimated enrollment is 147, and the primary completion date is projected to be October 31, 2025. [Extracted from the article]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results